The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.

Provided herein are compositions and methods for inducing cell death in a regulated manner, for example in a safety switch system. Inducible cell death can be triggered by ligand binding to a one or more ligand binding domains. Cell death can include induction of apoptosis.

The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.

[Problems] To provide a technique for efficiently incorporating an agent having to function in muscle tissue, which is not sufficiently incorporated into muscle tissue when administered in body, into muscle tissue, particularly muscle tissue composed of skeletal muscle or cardiac muscle. [Solution] A conjugate of an anti-human transferrin receptor antibody and an agent, wherein the agent is a biologically active agent that should function in muscle tissue, e.g., a lysosomal enzyme such as acid -glucosidase, -galactosidase A.

The present disclosure relates to compositions and methods of using the same for the treatment of various metabolic diseases and related disorders (e.g. diabetes mellitus, NAFLD, obesity, metabolic syndrome). The compositions and methods of the disclosure relate to the administration of an arginine-degrading enzyme.

Described herein are methods and compositions related to compositions comprising combinations of V/K-type and V/E-type docking peptides and uses thereof, e.g., to deliver therapeutic agents to treat certain conditions such as cancer, infection, or trauma.

Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.

Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided.

The present invention relates to an antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance. When the physiologically active substance modified with the conjugating peptide according to the present invention is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.

The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.